Status:
TERMINATED
Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes
Lead Sponsor:
Yale University
Collaborating Sponsors:
Juvenile Diabetes Research Foundation
Conditions:
Type 1 Diabetes
De Novo Lipogenesis
Eligibility:
All Genders
13-22 years
Phase:
NA
Brief Summary
The purpose of this study is to quantitate hepatic de novo lipogenesis (DNL) in youth with poorly-controlled type 1 diabetes (T1D) (HbA1c \>8.5%), youth with T1D who achieve targeted glycemic control ...
Detailed Description
What is not known, is whether hepatic de novo lipogenesis (DNL) contributes to dyslipidemia in this in patients with type 1 diabetes (T1D). The aim of the study is to test the hypothesis that an enhan...
Eligibility Criteria
Inclusion
- HbA1c \>8.5% for the group with poorly controlled diabetes
- HbA1c \<7.5% for the well-controlled patients
- T1D for at least 12 months (T1D groups only)
- Negative pregnancy test (all groups)
Exclusion
- Baseline creatinine \>1
- Being on medications affecting glucose concentrations other than insulin
- Positive pregnancy test
- Endocrinopathies
Key Trial Info
Start Date :
November 21 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2022
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT04101045
Start Date
November 21 2019
End Date
March 30 2022
Last Update
February 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University School of Medicine
New Haven, Connecticut, United States, 06511